Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate

British Journal of Clinical Pharmacology

Volumn 59, Issue 5, 2005, Pages 598-601

  Snell, Paul ^a   Dave, Nisha ^b   Wilson, Katie ^a   Rowell, Lucy ^a   Weil, Angelica ^c   Galitz, Lawrence ^d   Robson, Richard ^e  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b HOFFMANN LA ROCHE INC   (United States)

^c APEX Research   (Germany)

^d South Florida Bioavailability Clinic   (United States)

^e Christchurch Clinical Studies Trust   (New Zealand)

Author keywords

Hepatic impairment influenza; Oseltamivir; Oseltamivir carboxylate; Pharmacokinetics

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; DRUG METABOLITE; OSELTAMIVIR;

ADULT; AGE; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CLEARANCE; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FEMALE; GENDER; HUMAN; LIVER DISEASE; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE;

ACETAMIDES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; OSELTAMIVIR;

EID: 18244383751     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02340.x     Document Type: Article

References (6)

1. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37: 471-84.
2. Oo C, Barrett J, Hill G, et al. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs 2001; 3: 229-36.
3. Huet PM, Villeneuve JP, Fenyves D. Drug elimination in chronic liver disease. J Hepatol 1997; 26(Suppl 2): 63-72.
4. FDA Draft: Guidance for Industry, November 1999: Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling.
5. Wiltshire H, Wiltshire B, Citron A, et al. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatographr B Biomed Sci Appl 2000; 745: 373-88.
6. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283: 1016-24.